Literature DB >> 22871239

Lung dose calculation with SPECT/CT for ⁹⁰Yittrium radioembolization of liver cancer.

Naichang Yu1, Shaym M Srinivas, Frank P Difilippo, Sankaran Shrikanthan, Abraham Levitin, Gordon McLennan, James Spain, Ping Xia, Allan Wilkinson.   

Abstract

PURPOSE: To propose a new method to estimate lung mean dose (LMD) using technetium-99m labeled macroaggregated albumin ((99m)Tc-MAA) single photon emission CT (SPECT)/CT for (90)Yttrium radioembolization of liver tumors and to compare the LMD estimated using SPECT/CT with clinical estimates of LMD using planar gamma scintigraphy (PS). METHODS AND MATERIALS: Images of 71 patients who had SPECT/CT and PS images of (99m)Tc-MAA acquired before TheraSphere radioembolization of liver cancer were analyzed retrospectively. LMD was calculated from the PS-based lung shunt assuming a lung mass of 1 kg and 50 Gy per GBq of injected activity shunted to the lung. For the SPECT/CT-based estimate, the LMD was calculated with the activity concentration and lung volume derived from SPECT/CT. The effect of attenuation correction and the patient's breathing on the calculated LMD was studied with the SPECT/CT. With these effects correctly taken into account in a more rigorous fashion, we compared the LMD calculated with SPECT/CT with the LMD calculated with PS.
RESULTS: The mean dose to the central region of the lung leads to a more accurate estimate of LMD. Inclusion of the lung region around the diaphragm in the calculation leads to an overestimate of LMD due to the misregistration of the liver activity to the lung from the patient's breathing. LMD calculated based on PS is a poor predictor of the actual LMD. For the subpopulation with large lung shunt, the mean overestimation from the PS method for the lung shunt was 170%.
CONCLUSIONS: A new method of calculating the LMD for TheraSphere and SIR-Spheres radioembolization of liver cancer based on (99m)Tc-MAA SPECT/CT is presented. The new method provides a more accurate estimate of radiation risk to the lungs. For patients with a large lung shunt calculated from PS, a recalculation of LMD based on SPECT/CT is recommended.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871239     DOI: 10.1016/j.ijrobp.2012.06.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.

Authors:  Mattijs Elschot; Johannes F W Nijsen; Marnix G E H Lam; Maarten L J Smits; Jip F Prince; Max A Viergever; Maurice A A J van den Bosch; Bernard A Zonnenberg; Hugo W A M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-13       Impact factor: 9.236

2.  Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?

Authors:  Mohammad Elsayed; Bernard Cheng; Minzhi Xing; Ila Sethi; David Brandon; David M Schuster; Zachary Bercu; James Galt; Bruce Barron; Nima Kokabi
Journal:  Cardiovasc Intervent Radiol       Date:  2020-10-01       Impact factor: 2.740

Review 3.  Side effects of yttrium-90 radioembolization.

Authors:  Ahsun Riaz; Rafia Awais; Riad Salem
Journal:  Front Oncol       Date:  2014-07-29       Impact factor: 6.244

4.  Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization.

Authors:  Yung Hsiang Kao; Butch M Magsombol; Ying Toh; Kiang Hiong Tay; Pierce Kh Chow; Anthony Sw Goh; David Ce Ng
Journal:  EJNMMI Res       Date:  2014-06-29       Impact factor: 3.138

5.  Review of diagnostic uses of shunt fraction quantification with technetium-99m macroaggregated albumin perfusion scan as illustrated by a case of Osler-Weber-Rendu syndrome.

Authors:  Kabilan Chokkappan; Anbalagan Kannivelu; Sivasubramanian Srinivasan; Suresh Balasubramanian Babut
Journal:  Ann Thorac Med       Date:  2016 Apr-Jun       Impact factor: 2.219

6.  Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study.

Authors:  Arthur J A T Braat; Jip F Prince; Rob van Rooij; Rutger C G Bruijnen; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

7.  The effect of selective internal radiation therapy with yttrium-90 resin microspheres on lung carbon monoxide diffusion capacity.

Authors:  Tunc Ones; Emel Eryuksel; Feyyaz Baltacioglu; Berrin Ceyhan; Tanju Yusuf Erdil
Journal:  EJNMMI Res       Date:  2017-12-29       Impact factor: 3.138

8.  Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy.

Authors:  Justin K Mikell; Armeen Mahvash; Wendy Siman; Firas Mourtada; S Cheenu Kappadath
Journal:  EJNMMI Phys       Date:  2015-07-30

9.  Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts?

Authors:  Jens M Theysohn; Marcus Ruhlmann; Stefan Müller; Alexander Dechene; Jan Best; Johannes Haubold; Lale Umutlu; Guido Gerken; Andreas Bockisch; Thomas C Lauenstein
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

Review 10.  Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.

Authors:  Etienne Garin; Yan Rolland; Sophie Laffont; Julien Edeline
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.